Last update 21 Nov 2024

Human papillomavirus vaccine TA-CIN(Xenova Ltd.)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Therapeutic vaccine, Genetically engineered subunit vaccine

Synonyms

Human papillomavirus vaccine TA-CIN, Recombinant HPV16 L2E6E7 fusion protein vaccine, TA-CIN

+ [2]

Target

HPV E6 x HPV E7 x HPV L2

Mechanism

HPV E6 inhibitors(HPV E6 inhibitors), HPV E7 inhibitors(HPV E7 inhibitors), HPV L2 inhibitors(Papillomavirus minor capsid protein inhibitors)

+ [1]

Therapeutic Areas

NeoplasmsUrogenital DiseasesInfectious Diseases

Active Indication

Vulvar NeoplasmsHuman Papillomavirus-16 Positive

Inactive Indication

Uterine Cervical DysplasiaVulvar intraepithelial neoplasia

Originator Organization

Xenova Ltd.

Active Organization

Cancer Research Technology Ltd.

Xenova Ltd.Cantab Pharmaceuticals Plc

+ [1]

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

100 Clinical Results associated with Human papillomavirus vaccine TA-CIN(Xenova Ltd.)

100 Translational Medicine associated with Human papillomavirus vaccine TA-CIN(Xenova Ltd.)

100 Patents (Medical) associated with Human papillomavirus vaccine TA-CIN(Xenova Ltd.)

Literatures (Medical) associated with Human papillomavirus vaccine TA-CIN(Xenova Ltd.)

01 Dec 2023·Cutaneous and ocular toxicology

Endothelial loss following postoperative intracameral triamcinolone acetonide and subconjunctival dexamethasone injections.

Article

Author: Sali, Fatma ; Aykut, Veysel ; Oguz, Halit ; Hepokur, Mustafa ; Durmus, Ebubekir ; Esen, Fehim ; Kunbaz, Ahmad

OBJECTIVESTo compare endothelial toxicity and efficacy of two local steroid injections (intracameral triamcinolone acetonide and subconjunctival dexamethasone) in controlling postoperative inflammation following pars plana vitrectomy (PPV) combined with phacoemulsification cataract surgery.METHODSThis cohort included 54 patients that underwent combined surgery and received either intracameral triamcinolone acetonide injections (n = 27, IC-TA group) or subconjunctival dexamethasone (n = 27, Sc-Dex group) injections at the end of the surgery. All participants had at least 4 months or longer follow-up. A detailed ophthalmologic examination including intraocular pressure (IOP) measurement and specular microscopy was performed at every visit.RESULTSEndothelial cell density (ECD) reduced significantly in IC-TA group postoperatively (2418 vs. 2249, p = 0.019), while it did not change significantly in Sc-Dex group (2541 vs. 2492, p = 0.247). Postoperative ECD was also significantly lower in IC-TA group compared to Sc-Dex group (p = 0.011). Preoperative and postoperative IOP values remained unchanged both in IC-TA and Sc-Dex groups (p = 0.424 and p = 0.523, respectively). However, 4 patients in IC-TA group and 5 patients in the Sc-Dex group needed glaucoma medications. The postoperative need for glaucoma medications was similar between the groups (p = 0.347). Postoperative inflammation was well controlled in both groups and none of the patients developed fibrin membrane or synechiae postoperatively.CONCLUSIONBoth treatments were effective in controlling postoperative inflammation, but patients in IC-TA group experienced significantly higher endothelial loss. Sc-Dex injections are safer in terms of endothelial loss and preferable to control postoperative inflammation following complex intraocular surgeries.

06 Oct 2023·Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

[Current status of clinical trials of HPV therapeutic vaccines].

Review

Author: Cun, Y N ; Wang, M Y

Cervical cancer mainly caused by human papillomavirus (HPV) infection has become a public health issue, which seriously threatens women 's health. To prevent HPV infection, the currently used prophylactic vaccines mainly induce a humoral immune response in the host, thereby generating neutralizing antibodies. In contrast, the design goal of therapeutic HPV vaccines is to induce a cell-mediated immune response in the host, primarily driven by Th1 cells, aiming to clear existing viral infections and slow down or inhibit tumor progression. Currently, several therapeutic HPV vaccines based on different mechanisms and techniques have entered clinical trials. This review will summarize the progress of these clinical trials, providing reference for the research and development of therapeutic HPV vaccines.

01 Apr 2023·European Journal of Immunology

Distinct spatiotemporal features of microglia and monocyte‐derived macrophages in glioma

Article

Author: Stein, Reuven ; Banerjee, Kaveri ; Blinder, Pablo ; Ratzabi, Avinoam ; Caspit, Itai M ; Ganon, Or ; Jung, Steffen

AbstractGliomas are the most frequent primary tumors of the brain. Glioma progression is regulated by the tumor microenvironment, which is mainly composed of tumor‐associated microglia (TA‐MG) and monocyte‐derived macrophages (MDM). Recent studies have highlighted the distinct properties of these cells in glioma progression. However, their spatiotemporal alteration during tumor progression has not been fully explored. Using a genetic lineage tracing approach, we show that TA‐MG and MDMs differ in their spatiotemporal distribution and interaction with other components of the glioma microenvironment. MDM were present only inside the tumor, whereas TA‐MG accumulated both outside and inside the tumor. However, TA‐MG was eliminated from the tumor mass as the tumor progressed. Depletion of MDM led to enhanced occupancy of TA‐MG in the tumor core, indicating that TA‐MG elimination was regulated by MDM. TA‐MG and MDM are heterogeneous cell populations whose compositions and properties can change during tumor progression. Finally, MG, TA‐MG and MDM were enriched in the perivascular area (PVA) compared to more distal blood vessel‐associated areas. However, inside the tumor, the MDM enrichment in PVA was higher than that in TA‐MG. Collectively, we established that TA‐MG and MDM exhibit different spatiotemporal features in glioma, suggesting distinctive roles during tumor progression.

100 Deals associated with Human papillomavirus vaccine TA-CIN(Xenova Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05809

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Uterine Cervical Dysplasia	Phase 2	NL	-	-
Vulvar Neoplasms	Phase 2	-	Xenova Ltd.	-
Vulvar Neoplasms	Phase 2	-	Cancer Research Technology Ltd.	-
Vulvar intraepithelial neoplasia	Phase 1	GB	-	22 Oct 2001
Human Papillomavirus-16 Positive	Preclinical	NL	Academisch Ziekenhuis Leiden	01 Jun 2001
Human Papillomavirus-16 Positive	Preclinical	GB	Cantab Pharmaceuticals Plc	01 Jun 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Human papillomavirus vaccine TA-CIN(Xenova Ltd.)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation